Revenue Showdown: Veracyte, Inc. vs Supernus Pharmaceuticals, Inc.

Biotech Revenue Race: Veracyte vs. Supernus

__timestampSupernus Pharmaceuticals, Inc.Veracyte, Inc.
Wednesday, January 1, 201412204500038190000
Thursday, January 1, 201514442700049503000
Friday, January 1, 201621500300065085000
Sunday, January 1, 201730223800071953000
Monday, January 1, 201840889700092008000
Tuesday, January 1, 2019392755000120368000
Wednesday, January 1, 2020520397000117483000
Friday, January 1, 2021579775000219514000
Saturday, January 1, 2022667238000296536000
Sunday, January 1, 2023607521000361051000
Loading chart...

Data in motion

Revenue Growth: A Tale of Two Biotechs

In the competitive landscape of biotechnology, Veracyte, Inc. and Supernus Pharmaceuticals, Inc. have showcased remarkable revenue trajectories over the past decade. Since 2014, Supernus Pharmaceuticals has consistently outpaced Veracyte, with its revenue growing by over 400% by 2023. In contrast, Veracyte has seen an impressive growth of nearly 850% during the same period, reflecting its dynamic expansion strategy.

A Closer Look at the Numbers

By 2023, Supernus Pharmaceuticals reported a revenue of approximately $607 million, a slight dip from its peak in 2022. Meanwhile, Veracyte's revenue surged to around $361 million, marking a significant leap from its modest beginnings. This growth narrative highlights the evolving strategies and market adaptations of these two companies, offering insights into their future potential in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025